Gonadorelin Acetate: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 7 sources cited
Overview
Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), identical to the naturally produced decapeptide from the hypothalamus. It stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for fertility diagnostics and treatment, and in the peptide community for maintaining testicular function during testosterone replacement therapy (TRT) or anabolic steroid use.
Mechanism of Action
Gonadorelin binds to GnRH receptors on gonadotroph cells in the anterior pituitary gland. This activates phospholipase C signaling, increasing intracellular calcium and triggering exocytosis of LH and FSH from secretory vesicles. The key pharmacological principle is that GnRH must be delivered in a pulsatile manner to maintain receptor sensitivity — continuous administration paradoxically downregulates GnRH receptors and suppresses gonadotropin release (this is the mechanism behind GnRH agonist therapies for prostate cancer). Given as true pulses by pump, gonadorelin restores the HPG axis in men with hypothalamic hypogonadism, raising testicular volume and producing sperm. Whether every-other-day injections maintain the axis during testosterone therapy has not been studied.
Gonadorelin Acetate Benefits: What the Research Shows
- Gonadorelin was FDA-approved as Factrel in 1982 and as the Lutrepulse pump kit in 1989, but Drugs@FDA lists every product on both applications as discontinued, so no approved human gonadorelin product is marketed in the US
- Pulsatile GnRH restored fertility in hypothalamic amenorrhea: 14 clomiphene-resistant women given 5 to 15 mcg pulses every 90 minutes ovulated in 83% of treatment cycles, with pregnancy after 54% of them (New England Journal of Medicine, 1984)
- In men with congenital hypogonadotropic hypogonadism, a pulsatile gonadorelin pump produced sperm earlier than hCG plus hMG therapy, a median of 6 months versus 14 (American Journal of Men's Health, 2019)
Gonadorelin Acetate Dosage
- Testicular maintenance during TRT: 100–200 mcg subcutaneous injection every other day or 2–3 times weekly
- Fertility stimulation: 50–100 mcg subcutaneous injection twice daily (mimicking physiological pulsatility)
- PCT (Post Cycle Therapy) protocol: 100 mcg twice daily for 2–4 weeks, often combined with clomiphene or tamoxifen
- Diagnostic use: 100 mcg IV bolus with LH measured at 15, 30, 45, 60, and 120 minutes
- For HCG alternative: community protocols use 200 mcg every other day. No study has compared gonadorelin with HCG during testosterone therapy.
- Subcutaneous injection into abdominal fat; can also be administered intramuscularly
- Timing: morning injection preferred to align with natural GnRH pulsatility
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Gonadorelin Acetate Side Effects & Safety
Known Side Effects
- Injection site reactions: mild redness, irritation
- Headache (uncommon, more frequent at higher doses)
- Transient nausea
- Flushing or lightheadedness immediately post-injection
- Potential for ovarian hyperstimulation in women (clinical fertility context only)
- With chronic overuse: paradoxical GnRH receptor desensitization and reduced LH/FSH output
Safety Profile
Gonadorelin was approved in the US in 1982, but both approved human products are discontinued, so what is sold now is compounded. It is identical to endogenous GnRH, which is the reason immunogenicity is expected to be low. At standard pulsatile doses, it maintains rather than disrupts the hypothalamic-pituitary-gonadal axis. The critical safety consideration is avoiding continuous administration, which causes receptor desensitization and gonadotropin suppression — the opposite of the desired effect. Contraindicated in GnRH-dependent tumors (prostate, breast), pregnancy, and those with known hypersensitivity. Women of reproductive age should use under medical supervision due to ovarian stimulation risk. Long-term safety has been described mainly in pump-delivered pulsatile therapy for hypogonadotropic hypogonadism; the injection schedules used outside that setting have not been studied. Drug interactions: may reduce efficacy of GnRH agonist/antagonist medications.
What to Expect
Week 1–2: LH and FSH levels begin to respond. Those who were suppressed (from TRT/AAS) may notice testicular 'fullness' returning. No dramatic subjective changes yet. Weeks 3–4: Testicular volume measurably increases in those who were atrophied. Intratesticular testosterone production improves. Libido may increase. Weeks 5–8: Stable hormonal maintenance established. Semen parameters improve if previously suppressed. Whether ongoing use during TRT maintains fertility or testicular health has not been studied. Blood work should confirm adequate LH/FSH response.
Common Stacks
Kisspeptin-10
Kisspeptin-10 stimulates GnRH release at the hypothalamic level, amplifying the signal that gonadorelin delivers directly to the pituitary
PT-141
PT-141 addresses sexual function through melanocortin pathways while gonadorelin maintains the hormonal foundation — complementary approaches
Ipamorelin
GH optimization via Ipamorelin paired with HPG axis maintenance via gonadorelin supports comprehensive male hormone health during TRT
Storage & Handling
Store lyophilized gonadorelin at 2–8°C for up to 6 months or -20°C for up to 12 months. Reconstitute with bacteriostatic water (1–2 mL). Refrigerate reconstituted solution and use within 2–4 weeks. Gonadorelin is somewhat fragile — avoid shaking, excessive heat, or repeated freeze-thaw. Clear, colorless solution.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Drugs@FDA: FACTREL (gonadorelin hydrochloride) for injection, NDA 018123. U.S. Food and Drug Administration. 1982.
- Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate) for injection, NDA 019687. U.S. Food and Drug Administration. 1989.
- Hurley DM, Brian R, Outch K, et al. Induction of ovulation and fertility in amenorrheic women by pulsatile low-dose gonadotropin-releasing hormone. N Engl J Med. 1984.
- Zhang L, Cai K, Wang Y, et al. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. Am J Mens Health. 2019.
- Cretu AM, Kamar AAM, Ciobica A, et al. Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review. Front Reprod Health. 2026.
- Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014.
- The Prohibited List 2026, section S2.2.1 Testosterone-stimulating peptides in males. World Anti-Doping Agency. 2026.
Related Peptides
Track Gonadorelin Acetate in Your Protocol
Log your Gonadorelin Acetate doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free